|
[Related PubMed/MEDLINE] Total Number of Papers: 30
|
|
|
[Display Entries]
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of
|
|
|
|
Abbreviation |
: CENU |
Long Form |
: chloroethylnitrosourea |
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2019 |
Chloroethylating anticancer drug-induced mutagenesis and its repair in Escherichia coli. |
AGT, ICLs, MMR, NER |
2 |
2010 |
A model of phospholipid biosynthesis in tumor in response to an anticancer agent in vivo. |
ODEs, PEMT |
3 |
2009 |
Combined methionine deprivation and chloroethylnitrosourea have time-dependent therapeutic synergy on melanoma tumors that NMR spectroscopy-based metabolomics explains by methionine and phospholipid metabolism reprogramming. |
Met |
4 |
2009 |
Mitochondrial bioenergetic background confers a survival advantage to HepG2 cells in response to chemotherapy. |
OXPHOS |
5 |
2008 |
Chemotherapy-induced bystander effect in response to several chloroethylnitrosoureas: an origin independent of DNA damage? |
--- |
6 |
2007 |
PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. |
PP2A |
7 |
2006 |
Bystander effects are induced by CENU treatment and associated with altered protein secretory activity of treated tumor cells: a relay for chemotherapy? |
cHsp, PEBP, ROS |
8 |
2006 |
Clinical response of O(6)-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients. |
GBMs, TTP |
9 |
2005 |
Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives. |
--- |
10 |
2003 |
Quantitative HRMAS proton total correlation spectroscopy applied to cultured melanoma cells treated by chloroethyl nitrosourea: demonstration of phospholipid metabolism alterations. |
HR-MAS, PLP, TOCSY |
11 |
2000 |
Development of a syngenic brain-tumor model resistant to chloroethyl-nitrosourea using a methylguanine DNA methyltransferase cDNA. |
MGMT |
12 |
1999 |
Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer. |
BBR, BCNU, CNU |
13 |
1999 |
N-(2-chloroethyl)-N-nitrosourea tethered to lexitropsin induces minor groove lesions at the p53 cDNA that are more cytotoxic than mutagenic. |
lex, N3-Alkyl-As |
14 |
1999 |
Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. |
GBMs, MGMT, TTP |
15 |
1999 |
Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment. |
6BG, WTMGMT |
16 |
1997 |
Evidence for nucleotide excision repair as a modifying factor of O6-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines. |
BCNU, MGMT |
17 |
1997 |
O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU. |
BCNU, BG, MGMT, V8MGMT |
18 |
1996 |
Enhancement effect of O6-fluorobenzylguanines on chloroethylnitrosourea cytotoxicity in tumor cells. |
ACNU, MGMT |
19 |
1996 |
Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. |
RT-PCR, TTP |
20 |
1996 |
Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. |
MGMT |
21 |
1995 |
The role of mRNA stability and transcription in O6-methylguanine DNA methyltransferase (MGMT) expression in Mer+ human tumor cells. |
MGMT, STZ |
22 |
1994 |
Disposition and metabolism of O6-alkylguanine-DNA alkyltransferase inhibitor in nude mice bearing human melanoma. |
BNAG |
23 |
1993 |
Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma. |
ARDS, DTIC, O6AT |
24 |
1993 |
DNA crosslinking, sister chromatid exchange and cytotoxicity of N-2-chloroethylnitrosoureas tethered to minor groove binding peptides. |
SCE |
25 |
1992 |
Modulation of BUdR labeling index in rat brain tumors following intracarotid ACNU administration. |
ACNU, BUdR, LI |
26 |
1992 |
Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. |
MTP |
27 |
1990 |
Comparisons between sensitive and resistant human tumor cell lines regarding effects of polyamine depletion on chloroethylnitrosourea efficacy. |
BCNU, DFMO, ISC, PA, STZ |
28 |
1989 |
Affinity purification and characterization of human O6-alkylguanine-DNA alkyltransferase complexed with BCNU-treated, synthetic oligonucleotide. |
--- |
29 |
1988 |
Aerobic and hypoxic toxicity of a new class of mixed-function drugs associating nitroimidazoles and chloroethylnitrosourea in nitrosourea-sensitive (Mer-) and -resistant (Mer+) human tumor cells. |
NI, NI-CENU |
30 |
1988 |
Formation of covalent complexes between human O6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides. |
BCNU |
|